Vaxcyte, Inc.

PCVX

$48.34

Name : Vaxcyte, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $6,328,008,704.00

EPSttm : -4.85

Vaxcyte, Inc.

$48.34

0.72%

$0.35

Float Short %

6.77

Margin Of Safety %

Put/Call OI Ratio

1.03

EPS Next Q Diff

0.18

EPS Last/This Y

-1.38

EPS This/Next Y

-0.73

Price

48.34

Target Price

Analyst Recom

1.2

Performance Q

52.35

Relative Volume

0.8

Beta

1.27

Ticker: PCVX

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-10-20	PCVX	42.9	0.39	14.71	7030
2025-10-21	PCVX	42.34	0.41	7.57	7136
2025-10-22	PCVX	42.63	0.42	0.65	7193
2025-10-23	PCVX	41.56	0.44	1.50	7505
2025-10-24	PCVX	42.22	0.44	1.50	7505
2025-10-27	PCVX	44.58	0.44	0.68	7517
2025-10-28	PCVX	44.61	0.46	0.04	8313
2025-10-29	PCVX	43.5	0.46	999.99	8361
2025-10-30	PCVX	44.75	0.47	0.14	8398
2025-10-31	PCVX	45.3	0.47	999.99	8402
2025-11-03	PCVX	42.84	0.47	4.39	8405
2025-11-04	PCVX	41.33	0.58	111.16	9330
2025-11-05	PCVX	40.3	1.02	0.23	11996
2025-11-06	PCVX	41.72	1.00	2.00	12176
2025-11-07	PCVX	41.66	1.02	0.00	12058
2025-11-10	PCVX	42.94	1.02	2.11	12064
2025-11-11	PCVX	45.69	1.02	0.00	12077
2025-11-12	PCVX	46.13	1.01	1.00	12098
2025-11-13	PCVX	45.55	1.01	0.10	12099
2025-11-14	PCVX	48.71	1.01	39.52	12106
2025-11-17	PCVX	48.4	1.03	0.50	12281
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-10-20	PCVX	42.90	-49.3	-	-4.77
2025-10-21	PCVX	42.31	-49.3	-	-4.77
2025-10-22	PCVX	42.51	-49.3	-	-4.77
2025-10-23	PCVX	41.56	-49.3	-	-4.77
2025-10-24	PCVX	42.22	-49.3	-	-4.77
2025-10-27	PCVX	44.61	-49.3	-	-4.77
2025-10-28	PCVX	44.57	-49.3	-	-4.77
2025-10-29	PCVX	43.44	-49.3	-	-4.77
2025-10-30	PCVX	44.75	-49.3	-	-4.77
2025-10-31	PCVX	45.28	-49.3	-	-4.77
2025-11-03	PCVX	42.82	-49.3	-	-4.77
2025-11-04	PCVX	41.31	-49.3	-	-4.77
2025-11-05	PCVX	40.30	-49.3	-	-4.77
2025-11-06	PCVX	41.72	-49.3	-	-4.77
2025-11-07	PCVX	41.65	-49.3	-	-4.77
2025-11-10	PCVX	42.92	-49.3	-	-4.77
2025-11-11	PCVX	45.66	-38.4	-	-5.09
2025-11-12	PCVX	46.12	-34.8	-	-5.18
2025-11-13	PCVX	45.53	-34.8	-	-5.18
2025-11-14	PCVX	48.71	-34.8	-	-5.18
2025-11-17	PCVX	48.34	-34.8	-	-5.18
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-10-20	PCVX	0.00	2.80	8.84
2025-10-21	PCVX	0.00	2.80	8.84
2025-10-22	PCVX	0.00	2.80	8.84
2025-10-23	PCVX	0.00	2.80	8.84
2025-10-24	PCVX	0.00	2.80	8.84
2025-10-27	PCVX	0.00	2.96	7.99
2025-10-28	PCVX	0.00	2.96	7.99
2025-10-29	PCVX	0.00	2.96	7.99
2025-10-30	PCVX	0.00	2.96	7.99
2025-10-31	PCVX	0.00	2.96	7.99
2025-11-03	PCVX	0.00	2.67	7.99
2025-11-04	PCVX	0.00	2.67	7.99
2025-11-05	PCVX	0.00	2.67	7.99
2025-11-06	PCVX	0.00	2.67	7.99
2025-11-07	PCVX	0.00	2.67	7.92
2025-11-10	PCVX	0.00	2.35	7.92
2025-11-11	PCVX	0.00	2.35	7.92
2025-11-12	PCVX	0.00	2.35	6.78
2025-11-13	PCVX	0.00	2.35	6.78
2025-11-14	PCVX	0.00	2.35	6.78
2025-11-17	PCVX	0.00	7.49	6.77
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-1.56

Avg. EPS Est. Current Quarter

-1.37

Avg. EPS Est. Next Quarter

-1.38

Insider Transactions

Institutional Transactions

7.49

Beta

1.27

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

60.1

Max Drawdown 5-Year %

-76.2

Target Price

P/E

Forward P/E

PEG

P/S

P/B

2.17

P/Free Cash Flow

EPS

-4.92

Average EPS Est. Cur. Y

-5.18

EPS Next Y. (Est.)

-5.91

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.8

Return on Equity vs Sector %

-49.7

Return on Equity vs Industry %

-34.7

EPS 1 7Days Diff

-0.5

EPS 1 30Days Diff

-0.41

EBIT Estimation

Vaxcyte, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 414

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; and VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

stock quote shares PCVX – Vaxcyte, Inc. Stock Price stock today

news today PCVX – Vaxcyte, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch PCVX – Vaxcyte, Inc. yahoo finance google finance

stock history PCVX – Vaxcyte, Inc. invest stock market

stock prices PCVX premarket after hours

ticker PCVX fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: PCVX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y